BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11384869)

  • 1. Estrogen regulated proteases and antiproteases in ovarian and breast cancer cells.
    Rochefort H; Chalbos D; Cunat S; Lucas A; Platet N; Garcia M
    J Steroid Biochem Mol Biol; 2001; 76(1-5):119-24. PubMed ID: 11384869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Estrogens, cathepsin D and metastasis in cancers of the breast and ovary: invasion or proliferation?].
    Rochefort H
    C R Seances Soc Biol Fil; 1998; 192(2):241-51. PubMed ID: 9841098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview.
    Rochefort H; Platet N; Hayashido Y; Derocq D; Lucas A; Cunat S; Garcia M
    J Steroid Biochem Mol Biol; 1998 Apr; 65(1-6):163-8. PubMed ID: 9699869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix-degrading proteases in hormone-dependent breast cancer.
    Dickson RB; Shi YE; Johnson MD
    Breast Cancer Res Treat; 1994; 31(2-3):167-73. PubMed ID: 7881096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormones and breast cancer in vitro.
    Dickson RB; Thompson EW; Lippman ME
    Hum Cell; 1989 Sep; 2(3):219-30. PubMed ID: 2519209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasion of interstitial matrix by a novel cell line from primary peritoneal carcinosarcoma, and by established ovarian carcinoma cell lines: role of cell-matrix adhesion molecules, proteinases, and E-cadherin expression.
    Kokenyesi R; Murray KP; Benshushan A; Huntley ED; Kao MS
    Gynecol Oncol; 2003 Apr; 89(1):60-72. PubMed ID: 12694655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B.
    Kobayashi H; Ohi H; Sugimura M; Shinohara H; Fujii T; Terao T
    Cancer Res; 1992 Jul; 52(13):3610-4. PubMed ID: 1617632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen-induced lysosomal proteases secreted by breast cancer cells: a role in carcinogenesis?
    Rochefort H; Capony F; Garcia M; Cavaillès V; Freiss G; Chambon M; Morisset M; Vignon F
    J Cell Biochem; 1987 Sep; 35(1):17-29. PubMed ID: 3312245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells.
    Hall JM; Korach KS
    Mol Endocrinol; 2003 May; 17(5):792-803. PubMed ID: 12586845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer.
    Ruppert C; Ehrenforth S; Scharrer I; Halberstadt E
    Cancer Detect Prev; 1997; 21(5):452-9. PubMed ID: 9307848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antiproteases in the pathogenesis of neoplastic diseases].
    Dabrowska M
    Przegl Lek; 1998; 55(9):475-9. PubMed ID: 10085727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteases and protease inhibitors in tumor progression.
    DeClerck YA; Imren S; Montgomery AM; Mueller BM; Reisfeld RA; Laug WE
    Adv Exp Med Biol; 1997; 425():89-97. PubMed ID: 9433492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of GPER on proliferation, migration and invasion in ligand-independent manner in human ovarian cancer cell line SKOV3.
    Yan Y; Jiang X; Zhao Y; Wen H; Liu G
    Cell Biochem Funct; 2015 Dec; 33(8):552-9. PubMed ID: 26526233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
    Della Porta P; Soeltl R; Krell HW; Collins K; O'Donoghue M; Schmitt M; Krüger A
    Anticancer Res; 1999; 19(5B):3809-16. PubMed ID: 10628317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells.
    Briozzo P; Morisset M; Capony F; Rougeot C; Rochefort H
    Cancer Res; 1988 Jul; 48(13):3688-92. PubMed ID: 3378211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms.
    Platet N; Cunat S; Chalbos D; Rochefort H; Garcia M
    Mol Endocrinol; 2000 Jul; 14(7):999-1009. PubMed ID: 10894150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells.
    Gooch JL; Lee AV; Yee D
    Cancer Res; 1998 Sep; 58(18):4199-205. PubMed ID: 9751635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens.
    Hua W; Christianson T; Rougeot C; Rochefort H; Clinton GM
    J Steroid Biochem Mol Biol; 1995 Dec; 55(3-4):279-89. PubMed ID: 8541224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 52-kDa estrogen-induced protein secreted by MCF7 cells is a lysosomal acidic protease.
    Morisset M; Capony F; Rochefort H
    Biochem Biophys Res Commun; 1986 Jul; 138(1):102-9. PubMed ID: 3527155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogens and epithelial ovarian cancer.
    Cunat S; Hoffmann P; Pujol P
    Gynecol Oncol; 2004 Jul; 94(1):25-32. PubMed ID: 15262115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.